Barry J. Simon - 24 Jun 2026 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Reporting relationship: Director
Issuer ticker: IBRX
Reported as of: 24 Jun 2026
Net transaction value: -$196,908
SEC form: 4
Accepted by SEC: 26 Jun 2026, 21:00:07 UTC
Prior SEC filing: 05 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ David C. Sachs, as Attorney-in-Fact

Key filing fact

Barry J. Simon filed Form 4 for ImmunityBio, Inc. (IBRX) on 26 Jun 2026.

Key facts

This page summarizes Barry J. Simon's Form 4 filing for ImmunityBio, Inc. (IBRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 26 Jun 2026, 21:00.

Change

Previous filing in this sequence was filed on 05 Jun 2026.
Current net transaction value: -$196,908.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001647994 Primary reporting owner

Simon Barry J.

Relationship: Director
Address: C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO
Signature: /s/ David C. Sachs, as Attorney-in-Fact
Signature date: 26 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IBRX transaction

Common Stock

Sale

Transaction value: $196,908
Shares: -25,000
Change %: -0.88%
Price: $7.88
Shares after: 2,802,788
Date: 24 Jun 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2025.

Footnote F2

Represents the weighted average share price of an aggregate total of 25,000 shares sold in the price range of $7.875 to $7.885 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.